Pharmaceutical giant Eli Lilly, now valued at over $1 trillion, is evaluating India for potential manufacturing and biotech partnerships. CEO David A. Ricks highlighted the country's scientific talent as a key factor for growth. Investors are watching these plans closely as the firm manages strong global demand for its obesity drugs while facing increasing competition and pricing pressures.
Eli Lilly is looking at India as a core part of its future expansion. CEO David A. Ricks has confirmed that the company is studying the Indian market for potential manufacturing facilities and partnerships with local biotech firms. This move comes at a time when the US-based pharmaceutical major has solidified its position as a global leader, becoming the first in the healthcare sector to surpass a $1 trillion market capitalization.
The company's expansion plans are fueled by the rapid success of its metabolic drugs, such as Mounjaro and Zepbound. In the second quarter of 2026, Eli Lilly reported revenue of $23 billion, a strong 48% jump compared to the previous year. Following this performance, the company raised its full-year 2026 revenue guidance to a range of $85 billion to $87 billion. As of October 1, 2026, the company’s stock was trading near $1,157.
Scaling Operations in India
The CEO pointed to India’s deep pool of scientific talent and growing healthcare ecosystem as key reasons for the interest. By potentially deepening its local footprint, Eli Lilly aims to secure its supply chain and research capabilities. This is not entirely new for the company, which already operates a research hub in Bengaluru, but the current discussion suggests a shift toward larger-scale infrastructure or direct investments in new health areas like women's health, psychiatry, and infectious disease.
Risks and Market Challenges
While the growth story remains strong, investors face specific risks. The highly successful GLP-1 weight-loss drugs are under pressure from increasing competition, which could lead to lower prices and thinner profit margins over time. Additionally, the company's aggressive strategy of pursuing acquisitions in underfunded medical areas brings integration risks—ensuring that new companies and technologies successfully fit into the larger business structure can be both difficult and costly.
Furthermore, the company’s reliance on tiered pricing strategies to improve global access, while aimed at broader market penetration, creates complexity in maintaining stable revenue streams across different international markets with varying insurance and regulatory policies. The company must balance its commercial goals with these international access requirements.
The next important updates for investors will be any concrete announcements regarding new manufacturing plants or specific biotech partnerships in India. Market participants may also track how the company manages profit margin pressure as competition intensifies globally and how it integrates any new acquisitions into its existing business.